Multiple Myeloma and Kidney Disease
Open Access
- 27 October 2013
- journal article
- review article
- Published by Hindawi Limited in The Scientific World Journal
- Vol. 2013, 1-9
- https://doi.org/10.1155/2013/487285
Abstract
Multiple myeloma (MM) has a high incidence rate in the elderly. Responsiveness to treatments differs considerably among patients because of high heterogeneity of MM. Chronic kidney disease (CKD) is a common clinical feature in MM patients, and treatment-related mortality and morbidity are higher in MM patients with CKD than in patients with normal renal function. Recent advances in diagnostic tests, chemotherapy agents, and dialysis techniques are providing clinicians with novel approaches for the management of MM patients with CKD. Once reversible factors, such as hypercalcemia, have been corrected, the most common cause of severe acute kidney injury (AKI) in MM patients is tubulointerstitial nephropathy, which results from very high circulating concentrations of monoclonal immunoglobulin free light chains (FLC). In the setting of AKI, an early reduction of serum FLC concentration is related to kidney function recovery. The combination of extended high cutoff hemodialysis and chemotherapy results in sustained reductions in serum FLC concentration in the majority of patients and a high rate of independence from dialysis.Keywords
This publication has 73 references indexed in Scilit:
- Cancer risk among elderly persons with end-stage renal disease: a population-based case–control studyBMC Nephrology, 2012
- The pathogenesis and diagnosis of acute kidney injury in multiple myelomaNature Reviews Nephrology, 2011
- Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working GroupJournal of Clinical Oncology, 2010
- Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)Leukemia, 2009
- European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): A randomised control trialTrials, 2008
- Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failureBMC Nephrology, 2008
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple MyelomaThe New England Journal of Medicine, 2008
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injuryCritical Care, 2007
- Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimensJAMA, 1969